- Home
- TRML vs AUTL Comparison
TRML vs AUTL Comparison
Compare TRML & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRML
- AUTL
- Stock Information
- Founded
- TRML 2021
- AUTL 2014
- Country
- TRML United States
- AUTL United Kingdom
- Employees
- TRML N/A
- AUTL N/A
- Industry
- TRML Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TRML Health Care
- AUTL Health Care
- Exchange
- TRML Nasdaq
- AUTL Nasdaq
- Market Cap
- TRML 598.9M
- AUTL 625.4M
- IPO Year
- TRML N/A
- AUTL 2018
- Fundamental
- Price
- TRML $47.65
- AUTL $1.32
- Analyst Decision
- TRML Hold
- AUTL Strong Buy
- Analyst Count
- TRML 12
- AUTL 5
- Target Price
- TRML $47.04
- AUTL $9.12
- AVG Volume (30 Days)
- TRML 1.6M
- AUTL 4.2M
- Earning Date
- TRML 11-06-2025
- AUTL 11-11-2025
- Dividend Yield
- TRML N/A
- AUTL N/A
- EPS Growth
- TRML N/A
- AUTL N/A
- EPS
- TRML N/A
- AUTL N/A
- Revenue
- TRML N/A
- AUTL $29,934,000.00
- Revenue This Year
- TRML N/A
- AUTL $634.25
- Revenue Next Year
- TRML N/A
- AUTL $93.16
- P/E Ratio
- TRML N/A
- AUTL N/A
- Revenue Growth
- TRML N/A
- AUTL 185.17
- 52 Week Low
- TRML $11.56
- AUTL $1.11
- 52 Week High
- TRML $47.70
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- TRML 94.40
- AUTL 26.05
- Support Level
- TRML $22.31
- AUTL $1.34
- Resistance Level
- TRML $47.69
- AUTL $1.46
- Average True Range (ATR)
- TRML 1.15
- AUTL 0.09
- MACD
- TRML 2.54
- AUTL 0.01
- Stochastic Oscillator
- TRML 99.80
- AUTL 7.25
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.